R&D channel feed – Endpoints News

R&D channel feed

Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis

Last week

Regenxbio says Duchenne gene therapy improved motor skills in five patients

Last week

Exclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drug

Last week

Sagimet's stock rises after China partner reports positive Phase 3 data in acne

Last week

AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis

Last week

Sionna selects which cystic fibrosis drug it will study in a mid-stage test

Last week

Lilly makes a move for long-acting incretins in tech deal with Swedish biotech

Last week

BioNTech presents impressive early data for PD-L1xVEGF in mesothelioma

Last week

At ASCO, cell therapies for deadly form of brain cancer make early strides

Last week

Lyra’s stock soars on Phase 3 success for chronic rhinosinusitis treatment

Last week

Regeneron makes $80M obesity deal with Hansoh

Last week

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Last week

Enhertu combo has the makings of a new standard in HER2-positive breast cancer

Last week

Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B

Last week

Kymera unveils ‘exceptional’ Phase 1 data for its Dupixent-in-a-pill program

Last week

Vera posts positive Phase 3 rare kidney disease data, but crowded market looms

Last week

In race with Merus, Bicara makes the case for two-year survival data

Last week

AstraZeneca details its oral SERD 'switching' regimen as feasibility questions remain

2 weeks ago

As life-saving checkpoint drugs move to earlier cancers, researchers debate how best to use them

2 weeks ago

Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug

2 weeks ago

Immatics reports more early-stage data for melanoma cell therapy with pivotal trial underway

3 weeks ago

Enhertu extends life by three months for some stomach cancer patients, study finds

3 weeks ago

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

3 weeks ago

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

3 weeks ago

First page Previous page 123 4 5 Next page Last page